Watchlist Price Alert

Sage Group (SGPYY)

OTC: SGPYY · Real-Time Price · USD

69.35

1.34 (1.98%)

At close: Jun 16, 2025, 3:58 PM

1.98% (1D)

Bid	69.26
Market Cap	16.82B
Revenue (ttm)	2.25B
Net Income (ttm)	267M
EPS (ttm)	1.88
PE Ratio (ttm)	36.89
Forward PE	35.27
Analyst	n/a

Ask	69.55
Volume	1,300
Avg. Volume (20D)	28,596
Open	69.52
Previous Close	68.00
Day's Range	69.33 - 69.79
52-Week Range	49.22 - 69.88
Beta	0.38

About SGPYY

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SGPYY

Website n/a

Full Company Profile

News

1 day ago · barrons.com

Sage Therapeutics Stock Soars 35% After Sale to Supernus. What We Know.

The deal is worth an initial $561 million, with potential for $234 million in add-ons.

1 day ago · businesswire.com

Shareholder Alert: The Ademi Firm Investigates Whether Sage Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Sage (NASDAQ: SAGE) for possible breaches of fiduciary duty and other violations of law in its transaction with Supernus Pharmaceuticals. Cl...

1 day ago · reuters.com

Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal

Drugmaker Supernus Pharmaceuticals said on Monday it will acquire Sage Therapeutics , which makes treatments for neurological conditions, in a deal worth up to $795 million.

1 week ago · newsfilecorp.com

Sage Potash Announces Second Financing Upsize to Targeted $6 Million

Vancouver, British Columbia--(Newsfile Corp. - June 9, 2025) - Sage Potash Corp. (TSXV: SAGE) (OTCQB: SGPTF) ("Sage Potash" or the "Company") is pleased to announce that, due to continued and signific...

1 week ago · accessnewswire.com

INVESTOR NOTICE: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. and Encourages Long-Term Investors to Contact the Firm - SAGE

PHILADELPHIA, PA / ACCESS Newswire / June 9, 2025 / Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning Sage Therapeutics, Inc. (NASDAQ:SAGE) ("Sage...

2 weeks ago · newsfilecorp.com

Sage Potash Announces Financing Upsize to $5 Million

Vancouver, British Columbia--(Newsfile Corp. - May 28, 2025) - Sage Potash Corp. (TSXV: SAGE) (OTCQB: SGPTF) ("Sage Potash" or the "Company") is pleased to announce that, further to its May 9 and May ...

3 weeks ago · newsfilecorp.com

Sage Potash Announces Financing Update

Vancouver, British Columbia--(Newsfile Corp. - May 27, 2025) - Sage Potash Corp. (TSXV: SAGE) (OTCQB: SGPTF) ("Sage Potash" or the "Company") announces that, further to its May 9, 2025 news release, i...

3 weeks ago · zacks.com

All You Need to Know About Sage Group (SGPYY) Rating Upgrade to Strong Buy

Sage Group (SGPYY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago · newsfilecorp.com

Sage Potash Announces Shares for Debt Transactions

Vancouver, British Columbia--(Newsfile Corp. - May 16, 2025) - Sage Potash Corp. (TSXV: SAGE) (OTCQB: SGPTF) ("Sage Potash" or the "Company") announces shares for debt transactions for an aggregate of...

1 month ago · seekingalpha.com

The Sage Group plc (SGGEF) Q2 2025 Earnings Call Transcript

The Sage Group plc (OTCPK:SGGEF) Q2 2025 Earnings Call Transcript May 15, 2025 3:30 AM ET Company Participants Steve Hare - Chief Executive Officer Jonathan Howell - Chief Financial Officer Conference...

Load More News